Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9345
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aydin, Merve Arslan | - |
dc.contributor.author | Janapatla, Rajendra Prasad | - |
dc.contributor.author | Chen, Chyi-Liang | - |
dc.contributor.author | Li, Hsin-Chieh | - |
dc.contributor.author | Su, Lin-Hui | - |
dc.contributor.author | Chiu, Cheng-Hsun | - |
dc.date.accessioned | 2024-12-19T05:00:27Z | - |
dc.date.available | 2024-12-19T05:00:27Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.citation | Original Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9345 | - |
dc.description.abstract | Abstract Background/purpose: Serotype 3 has persisted to be an important cause of invasive pneumococcal disease in adults in the post-vaccine era. We aimed to investigate clinical and microbiological characteristics of Streptococcus pneumoniae serotype 3 infection in Taiwan and identify the risk factors associated with severe clinical outcome. Methods: A multicenter observational study was conducted to analyze serotype 3 isolates collected between 2012 and 2021. Demographics, comorbidities, and risk categories were statistically compared with clinical outcome. Antimicrobial susceptibility testing and multilocus sequence typing were performed. Results: A total of 146 isolates were collected, including 12 isolates regarded as colonizers. Among 134 infected cases, 54 (40.3%) were aged 65 and older. Mortality was significantly associated with diabetes mellitus, immunosuppression, immunodeficiency, high-risk status, and older age. Susceptibility rates were high to levofloxacin (98.9%), moxifloxacin (100%), vancomycin (100%), and ceftriaxone (97.3%). 25.3% (37/146) of the isolates showed intermediate susceptibility and 0.7% (1/146) showed resistance to penicillin. ST180 was the dominant seq Conclusions: Serotype 3 infection showed a high mortality rate, especially in patients with older ages and comorbidities. Although the incidence rates decreased during the COVID-19 pandemic, serotype 3 remained as an important cause of infection after the implementation of PCV13. Developing a more effective vaccine against serotype 3 and monitoring the antimicrobial-resistant sequence types are necessary. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | Streptococcus pneumoniae | en_US |
dc.subject | Serotype 3 | en_US |
dc.subject | Mortality | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Antimicrobial susceptibility | en_US |
dc.subject | Sequence type | en_US |
dc.title | Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 56 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
598-604.pdf | 842.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.